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Intravenous immunoglobulin (IVIg) is used in the therapy of various autoimmune and inflammatory
diseases. Recent studies in experimental models propose that anti-inflammatory effects of IVIg are mainly
mediated by a2,6-sialylated Fc fragments. These reports further suggest that a2,6-sialylated Fc fragments
interact with DC-SIGN1 cells to release IL-33 that subsequently expands IL-4-producing basophils.
However, translational insights on these observations are lacking. Here we show that IVIg therapy in
rheumatic patients leads to significant raise in plasma IL-33. However, IL-33 was not contributed by human
DC-SIGN1 dendritic cells and splenocytes. As IL-33 has been shown to expand basophils, we analyzed the
proportion of circulating basophils in these patients following IVIg therapy. In contrast to mice data, IVIg
therapy led to basophil expansion only in two patients who also showed increased plasma levels of IL-33.
Importantly, the fold-changes in IL-33 and basophils were not correlated and we could hardly detect IL-4 in
the plasma following IVIg therapy. Thus, our results indicate that IVIg-induced IL-33 is insufficient to
mediate basophil expansion in autoimmune patients. Hence, IL-33 and basophil-mediated
anti-inflammatory mechanism proposed for IVIg might not be pertinent in humans.
I
ntravenous immunoglobulin (IVIg) is a therapeutic preparation of normal pooled immunoglobulin G (IgG)
obtained from the plasma of several thousand healthy donors. High-dose IVIg (1–2 g/kg) is widely used in the
treatment of various autoimmune and inflammatory diseases including Kawasaki disease, idiopathic
thrombocytopenic purpura, Guillain-Barre´ syndrome, chronic inflammatory demyelinating polyneuropathy,
myasthenia gravis, autoimmune blistering diseases, inflammatory myopathies, graft versus host disease and
others1–4. The cellular and molecular mechanisms of action of IVIg in these diverse diseases remain incompletely
understood. However, available evidence both from experimental and clinical studies provide an indicator that
IVIg could benefit these diverse diseases via several mutually non-exclusive mechanisms2,5–10. These mechanisms
include inhibition of activation and functions of innate immune cells such as dendritic cells (DCs), monocytes,
macrophages and neutrophils; inhibition of pathogenic effector T cells such as Th1 and Th17 cells; expansion of
regulatory T cells (Tregs); modulation of B cell responses; and inhibition of complement pathways. In addition,
IVIg has been shown to inhibit inflammatory cytokines and to augment anti-inflammatory molecules such as IL-
10 and IL-1 receptor antagonist11–21.
IgGs are glycoproteins and contain fragment antigen-binding (Fab) regions that recognize antigens, and
fragment crystallizable (Fc) regions that exert effector functions upon binding to Fcc receptors. The Fc fragments
are glycosylated at Asn297 and recent studies in animal models advocate that anti-inflammatory effects of IVIg
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are mediated by a small fraction of antibodies that contain terminal
a2,6-sialylated glycans at Asn297. It was proposed that a2,6-sialy-
lated Fc fragments interact with dendritic cell-specific intercellular
adhesion molecule-3-grabbing non-integrin-positive (DC-SIGN1)
innate cells to release IL-33, which subsequently expands IL-4-pro-
ducing basophils22. However, translational insights on these observa-
tions are lacking. Therefore, we investigated whether high-dose IVIg
therapy induces IL-33 production in autoimmune patients, which in
turn would mediate basophil expansion and IL-4 responses.
Results
IVIg therapy induces IL-33 in autoimmune patients. Previous
work on the role of IL-33 in IVIg-mediated anti-inflammatory
effects was performed in K/BxN serum-induced murine arthritis
model. It should be noted that IVIg is not recommended for
rheumatoid arthritis due to its inefficacy to relieve inflammation4.
Therefore, K/BxN serum-induced murine arthritis model might not
provide factual image of the mechanisms of IVIg in autoimmune
patients. Earlier studies have indicated that IVIg therapy benefits
patients with inflammatory myopathies1,4. Therefore, by using
heparinized blood samples of these patients (cohort 1 patients), we
first investigated the repercussion of IVIg therapy on the induction of
IL-33. We found that, out of nine patients, six had minimal level of
plasma IL-33 prior to IVIg therapy. The pre-IVIg plasma level of IL-
33 was in the range of 150.75 6 79.52 pg/ml (n 5 9) (Fig. 1a).
Following IVIg therapy, with an exception of one patient, all
remaining patients had significant raise in plasma IL-33 and was
in the range of 492.23 6 130.30 pg/ml (n 5 9) (Fig. 1a). However,
the increase in IL-33 following IVIg therapy was heterogeneous and
was varying from 1.2 to 911-fold.
To confirm these results, we analyzed the plasma samples from
another cohort of patients with inflammatory myopathies (n 5 4) or
anti-neutrophil cytoplasmic antibody-associated vasculitis (n 5 3)
(cohort 2 patients). Importantly, these patients also showed signifi-
cant increase in plasma IL-33 following IVIg therapy (Fig. 1b) thus
confirming the results obtained with cohort 1 patients. The pre-IVIg
plasma level of IL-33 was 80.436 24.93 pg/ml (n 5 7) that increased
to 291.58 6 34.40 pg/ml following IVIg therapy. Together, these
results indicate that irrespective of pathologies, IVIg therapy in
patients leads to increased plasma level of IL-33.
IVIg-induced IL-33 is not associated with an expansion of baso-
phils. Basophils play a crucial role in the induction of Th2
responses23,24. Recent data from K/BxN serum-induced murine
arthritis model suggest that IVIg-induced IL-33 promotes basophil
expansion22. Therefore, we investigated changes in the circulating
basophils following IVIg therapy in cohort 1 patients. Basophils
were identified based on the expression of FceRI and CD203c
(Fig. 2a)25. In contrast to the results from murine model, we found
that IVIg therapy leads to basophil expansion only in two patients
who also showed increased plasma level of IL-33 (Fig. 2b). In other
patients, basophils were either declined or unaltered. The changes in
the proportion of basophils in the circulation following IVIg therapy
were not statistically significant. Importantly, the fold-changes in IL-
33 and basophils were not correlated (Fig. 2c). Also contrary to
previous report22, we could hardly detect IL-4 in the plasma of
patients following IVIg therapy. Thus, these results demonstrate
that IVIg therapy in patients does not lead to an expansion of
basophils. Of note, a recent data from murine models of collagen
antibody-induced arthritis and K/BxN serum transfer arthritis also
reveal that therapeutic effect of IVIg is independent of sialylation and
basophils26.
DC-SIGN-positive human innate cells do not produce IL-33 upon
IVIg exposure. DC-SIGN1 innate cells (or SIGN-R11 cells in the
murine spleen) were proposed to produce IL-33 upon interaction
with a2,6-sialylated Fc fragments of IVIg22. By generating
humanized DC-SIGN-transgenic mice, the authors found that
these transgenic mice express DC-SIGN on DCs, macrophages and
monocytes in the blood, bone marrow and spleen. Importantly,
higher percentage of monocytes in these transgenic mice expressed
DC-SIGN22.
We analyzed the expression of DC-SIGN in human myeloid cells.
Contrary to humanized DC-SIGN-transgenic mice, circulating
human monocytes did not express DC-SIGN whereas its expression
on macrophages was restricted to M2 type macrophages wherein up
to 28% cells were positive for DC-SIGN. We could observe high
expression of DC-SIGN (<100%) only in monocyte-derived DCs
(Mo-DCs) (Fig. 3a). In the human spleen, up to 24% splenocytes
were positive for DC-SIGN (Fig. 3b).
Therefore, we explored if Mo-DCs secrete IL-33 upon IVIg treat-
ment. In contrast to proposition by Ravetch and colleagues, we could
Figure 1 | Consequence of IVIg therapy in autoimmune patients on the
plasma level of IL-33. (a) Heparinized blood samples were obtained from
nine patients with inflammatory myopathies (Cohort 1 patients) before
(Pre-IVIg) and 2-3 days after initiation of IVIg therapy (Post-IVIg). IL-33
(pg/ml) in the plasma was measured by ELISA. Each symbol in the graph
represents individual patient. (b) IL-33 in the plasma of four inflammatory
myopathies and three anti-neutrophil cytoplasmic antibody-associated
vasculitis patients (Cohort 2 patients) before and post-IVIg therapy. The
statistical significance as determined by two-tailed Student-t-test is
indicated, where *, P , 0.05; **, P , 0.01.
www.nature.com/scientificreports
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detect secreted IL-33 from IVIg-exposed DC-SIGN1 Mo-DCs nei-
ther under non-inflammatory nor under inflammatory conditions
(Fig. 3c). Similarly, despite the presence of DC-SIGN1 cells in the
spleen, human splenocytes did not produce detectable levels of
IL-33 upon IVIg exposure both under inflammatory and non-
inflammatory conditions (Fig. 3c).
Discussion
Our results demonstrate that IVIg therapy induces IL-33 in
autoimmune patients thus confirming the previous observation
made in mice. However, IL-33 was not contributed either by splenic
DC-SIGN1 cells or myeloid DCs. Also, the amount of IL-33 induced
in the patients was not sufficient to expand basophils. It should be
noted that the quantity of IL-33 protein induced in the mice follow-
ing IVIg treatment was not presented in the previous report. In
addition, significant amount of data on IVIg was indirect rather than
direct demonstration of IVIg-mediated regulation of cytokine net-
work22. Authors showed that IVIg induces about 12-fold increase in
IL-33mRNA level. However, the contribution of this increased IL-33
mRNA towards IL-33 protein is not clear. Considering five liters as
total blood volume in adults, our results show that IVIg induces
<24606 650 ng of IL-33 (based on the data from cohort 1 patients).
However, to demonstrate the role of IL-33 in IVIg-mediated anti-
inflammatory effects, Anthony et al., injected 400 ng of IL-33 for
four consecutive days22. As mouse weighing 25 g would have
<1.5 ml of blood, based on the IL-33 data from patients, we could
infer that the amount of exogenous IL-33 injected into the mice
represents at least 540-times excess of IL-33 that otherwise induced
by IVIg. This might explain why IVIg failed to induce expansion of
basophils in the patients. Although in our study, patients’ sample size
was small, we included diseases such as inflammatory myopathies
and vasculitis that were shown to benefit from IVIg therapy. Further
investigations in a larger number of patients should confirm these
observations.
Figure 2 | Changes in the proportion of circulating basophils of
autoimmune patients following IVIg therapy.Heparinized blood samples
were obtained from cohort 1 patients with inflammatory myopathies
before (Pre-IVIg) and 2–3 days after initiation of IVIg therapy (Post-IVIg).
(a) Representative dot-plots showing basophils from cohort 1 patients
gated positive for FceRI and CD203c (b) Modulation of circulating
basophils following IVIg therapy (n 5 9). Basophils were analyzed in the
whole blood by flow cytometry. The statistical significance as determined
by two-tailed Student-t-test is indicated, where NS, non-significant.
(c) The correlation between fold-changes in IL-33 and basophils following
IVIg therapy.
Figure 3 | Effect of IVIg on the IL-33 production fromDC-SIGN1 human
innate cells. (a and b) Histograms showing the expression of DC-SIGN by
healthy donor’s monocyte-derived human dendritic cells (Mo-DCs) and
splenocytes. (c) IVIg does not induce IL-33 fromDC-SIGN1human innate
cells. Mo-DCs or human splenocytes (n 5 5 donors) were exposed to IVIg
either under non-inflammatory conditions or under inflammatory
conditions (TLR-stimuli or inflammatory cytokine cocktail) for 48 hours.
IL-33 in the culture supernatants was analyzed by ELISA.
www.nature.com/scientificreports
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The role of Fc-sialylation, DC-SIGN and Fcc receptor IIB
(FccRIIB) in the anti-inflammatory effects of IVIg has been debated
recently by several groups27. Mice and humans show wide variations
in the expression pattern of FccRs, and the phenotype and anatom-
ical distribution of innate cells. Unlike mice, human innate cells
express both activating FccRIIA and inhibitory FccRIIB.
Therefore, the proposition that IVIg enhances FccRIIB on effector
macrophages of mice without having corresponding data on
FccRIIA might provide a biased picture on the mechanisms of
IVIg. Gene array analysis could not confirm IVIg-mediated up-regu-
lation of FccRIIB in the patients with Kawasaki disease28. In line with
this report, another recent study failed to demonstrate enhanced
expression of FccRIIB on monocytes following IVIg therapy in chil-
dren with immune thrombocytopenia29. Also, FccR polymorphisms
did not predict response to IVIg in myasthenia gravis30. Although
DC-SIGN promoter 2336 A/G (rs4804803) polymorphism was
associated with susceptibility of Kawasaki disease, this variant was
found to be not associated with the occurrence of IVIg resistance31.
Of note, treatment response in Kawasaki disease is apparently assoc-
iated with sialylation levels of endogenous IgG but not therapeutic
IVIg32. All these data thus questions the relevance of DC-SIGN-
FccRIIB pathway of anti-inflammatory mechanisms of IVIg in
humans.
Several recent studies have challenged the concept of a2,6-
sialylated Fc fragments-mediated anti-inflammatory mechanism of
IVIg both in experimental models and in humans. IVIg could inhibit
human Th17 cell differentiation and expansion independent of anti-
gen presenting cells and hence independent of interaction of DC-
SIGN and a2,6-sialylated Fc fragments13–15. Also, F(ab’)2 fragments
of IVIg exerted similar effects thus pointing towards dispensability of
a2,6-sialylated Fc fragments in mediating the suppression of Th17
cells. We have demonstrated that DC-SIGN and a2,6-sialylated Fc
fragment interaction is dispensable for the anti-inflammatory activ-
ity of IVIg on human DCs33. F(ab’)2 fragments but not Fc fragments
of IVIg were shown to mediate Treg expansion by inducing cycloox-
ygenase-2-mediated prostaglandin E2 secretion in human myeloid
DCs andwas dependent in part onDC-SIGN19. Similarly, sialylation-
enriched F(ab’)2 fragments could inhibit interferon-a production
from toll-like receptor (TLR)7 and TLR9 stimulated human plasma-
cytoid DCs, although sialic acid itself was not required34.
In the previous reports, Ravetch and colleagues enriched sialic
acid-containing IgG-Fc by using sialic acid-specific lectin Sambu-
cus nigra agglutinin-based affinity fractionation22,35–37. However, by
using same fractionation method, Guhr et al., showed that IVIg
fractions depleted for the sialylated antibody fraction exert benefits
in a murine model of passive-immune thrombocytopenia similar to
that of intact IVIg. However, sialic acid-enriched IVIg fraction failed
to enhance platelets count in this model38. Similar sialic-acid inde-
pendent anti-inflammatory mechanisms were also reported in mur-
ine herpes simplex virus encephalitis model39. Further, Ka¨sermann
and colleagues showed that lectin fractionation of IVIg results in
increased sialylation of Fab fragments but not Fc fragments. By using
human whole blood stimulation assay either with lipopolysaccharide
or phytohaemagglutinin, they further showed that anti-inflammat-
ory effects of IVIg is associated with F(ab’)2 fraction of IVIg40. In
animal models of immune thrombocytopenia and multiple sclerosis,
the beneficial effects of IVIg were independent of Fc or F(ab’)2 -
sialylation and FccRIIB41–44. Based on these results, it was suggested
that genetic background of the mice and dose of IVIg are the critical
factors that determine the role of FccRIIB in IVIg-mediated bene-
ficial effects. In line with these observations, two studies have failed to
demonstrate the direct interaction between sialylated IgG Fc frag-
ment and DC-SIGN45,46. These data thus point out that a2,6-
sialylated Fc fragment-DC-SIGN-FccRIIBmechanismmerely repre-
sents one of the several anti-inflammatory mechanisms of IVIg that
were reported. Therefore, this anti-inflammatory pathway of IVIg
might be operational in certain pathologies and experimental models
and might not be considered as a universal mechanism.
It was proposed that in humanized DC-SIGN-transgenic mice,
DC-SIGN1 innate cells such as monocytes, macrophages and DCs
produce IL-33 upon interaction with a2,6-sialylated Fc fragments of
IVIg22. Recent reports show that IL-33 is an important player for the
promotion of Th2 responses and activatedDCs are one of the sources
of this cytokine47,48. We found that unlike monocytes from huma-
Table 1 | Summary of data for autoimmune rheumatic patients
Cohort 1 patients
Number Disease Age (years) Sex IVIg Additional treatments
1 Polymyositis 59 F CLAIRYGH 1 g/kg Methylprednisolone
2 Anti-SRP associated necrotizing myopathy 27 F CLAIRYGH 1 g/kg Prednisone, Methotrexate
3 Anti-HMGCR associated necrotizing myopathy 62 F CLAIRYGH 0.5 g/kg Prednisone, Methotrexate
4 Anti-HMGCR associated necrotizing myopathy 61 F CLAIRYGH 1 g/kg Prednisone, Methotrexate
5 Dermatomyositis 52 F CLAIRYGH 1 g/kg Prednisone, Methotrexate
6 Polymyositis associated with mixed connective
tissue disease and Sjo¨gren’s syndrome
41 F CLAIRYGH 1 g/kg Prednisone, Methotrexate
7 Anti-SRP associated necrotizing myopathy 40 M CLAIRYGH 1 g/kg Prednisone, Methotrexate
8 Anti-Mi2 associated unclassified myositis 30 M CLAIRYGH 1 g/kg Prednisone, Methotrexate
9 Polymyositis and probable associated Sjo¨gren’s
syndrome
70 F CLAIRYGH 1 g/kg Prednisone, Methotrexate
Cohort 2 patients
Number Disease Age (years) Sex IVIg Additional treatments
1 Dermatomyositis 22 F TEGELINEH 1g/kg Prednisone, Mycophenolate mofetil
2 Polymyositis 42 M TEGELINEH 1g/kg Prednisone, Methotrexate
3 Dermatomyositis 35 M TEGELINEH 1g/kg Prednisone
4 Polymyositis 46 F TEGELINEH 1g/kg Prednisone, ciclosporin
5 Microscopic polyangiitis 61 F TEGELINEH 1g/kg Prednisone
6 Wegener’s granulomatosis 62 M TEGELINEH 1g/kg None
7 Microscopic polyangiitis 61 M TEGELINEH 1g/kg Prednisone, Mycophenolate mofetil
SRP, Signal Recognition Particle; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase.
www.nature.com/scientificreports
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nized DC-SIGN-transgenic mice that were highly positive for DC-
SIGN, human monocytes hardly express DC-SIGN. Further, human
Mo-DCs despite expressing DC-SIGN, failed to produce IL-33 when
exposed to IVIg either under non-inflammatory or inflammatory
conditions. In wild type mice, it was suggested that a2,6-sialylated
Fc fragments bind to SIGN-R1 expressed on splenic marginal zone
macrophages35. Marginal zone macrophages are absent in human
spleen and data from humans show that spleen is dispensable for
the anti-inflammatory effects of IVIg. In line with this concept, by
using a passive model of induced immune thrombocytopenia, it was
shown that IVIg is fully functional in splenectomized mice although
this report supported the sialic acid and SIGN-R1-dependent
mechanisms of IVIg49. We found that despite the presence of DC-
SIGN1 innate cells in the human spleen, IVIg could not induce IL-33
from the splenocytes. All these data indicate that spleen and DC-
SIGN1 cells are dispensable for IVIg-mediated IL-33 induction in
humans. Thus, the source of IL-33 in humans following IVIg therapy
remains elusive. As IVIg is known to cause apoptosis of cells, we
suggest that secondary necrosis of late stage apoptotic cells could
release IL-3350–52. This process might depend on the signals provided
by anti-Fas IgG or anti-Siglec IgG in the IVIg preparations rather
than the repercussion of interaction of a2,6-sialylated Fc fragments
with DC-SIGN53,54. In addition, IL-33 is also constitutively expressed
in the nucleus of endothelial cells and epithelial cells in vivo55.
Methods
Patients.All experiments were performed in accordance with relevant guidelines and
regulations. We obtained heparinized blood samples of nine patients (cohort 1
patients) with inflammatory myopathies (Table 1). Patients were aged 49.1 6 15.2
years and include two men. Blood samples were obtained before and 2–3 days
following initiation of IVIg therapy (CLAIRYGH, Laboratoire Français du
Fractionnement et des Biotechnologies, France). Informed consent was obtained
from all the patients. The study was approved by CPP-Ile-de-France VI, Groupe
Hospitalier Pitie´-Salpeˆtrie`re, Paris. In addition, we also analyzed plasma samples of
seven rheumatic patients (cohort 2 patients) before and 2–3 days post-IVIg therapy
(TEGELINEH, Laboratoire Français du Fractionnement et des Biotechnologies). The
patients were aged 47 6 5.8 years (four men) and include inflammatory myopathies
and anti-neutrophil cytoplasmic antibody-associated vasculitis (Table 1).
Analysis of basophils. Red blood cells (RBCs) from heparinized blood samples of
cohort 1 patients were depleted by using HetaSepTM (Stemcell Technologies Sarl,
France) and nucleated cell suspension was obtained. Basophils were analyzed in RBC-
depleted cell suspension by flow cytometry (LSR II, BD Biosciences, France) using
fluorochrome-conjugated monoclonal antibodies to FceRI (Miltenyi Biotec, France)
and CD203c (eBioscience, France). Data were analyzed by FACSDivaTM software (BD
Biosciences).
Generation of monocyte-derived DCs. Buffy coats from the healthy donors were
purchased from Centre Necker-Cabanel, Etablissement Français du Sang (EFS),
Paris, France. Institut National de la Sante´ et de la Recherche Me´dicale-EFS ethical
committee permission (Nu12/EFS/079) was obtained for the use of buffy coats of
healthy donors. Peripheral blood mononuclear cells (PBMCs) were purified from the
buffy coats by density gradient centrifugation using Ficoll-paque PREMIUM (GE
healthcare, France). CD141 monocytes were isolated from PBMCs by using CD14
microbeads (Miltenyi Biotec). Purified monocytes were then cultured for 6 days in
RPMI-1640 medium plus 10% fetal calf serum (FCS) containing cytokines GM-CSF
(1000 IU/106 cells) and IL-4 (500 IU/106 cells) (both from Miltenyi Biotec) to obtain
DCs56. The purity of DCs was .98%. DC-SIGN expression on Mo-DCs was
examined by flow cytometry using fluorochrome-conjugated monoclonal antibodies
(BD Biosciences) and data were analyzed by FACSDivaTM and FlowJo softwares (Tree
Star, USA).
Isolation of human splenocytes. The remnant human spleen sections from
individuals submitted for pathological diagnosis were obtained from service
d’anatomie pathologique, Hoˆpital Europe´en Georges Pompidou, Paris, France. Only
healthy spleen tissues were used for the research purpose. Since the study did not
require additional sampling, an approval from an ethics committee was not required
under French law according to the article L.1121-1 of the public health code. The
article states that: The research organized and performed on human beings in the
development of biological knowledge and medical research are permitted under
the conditions laid down in this book and are hereinafter referred to by the term
‘‘biomedical research’’. The article further states that it does not imply under
conditions: For research in which all actions are performed and products used in the
usual way, without any additional or unusual diagnostic procedure or surveillance.
The spleen sections were collected in RPMI 1640 medium supplemented with
100 IU/ml penicillin, 100 mg/ml streptomycin, and 10% FCS. Single-cell suspension
of splenocytes was obtained by mechanical disaggregation of spleen tissue pieces by
using gentleMACS dissociator (Miltenyi Biotec) followed by filtration through 70-mm
nylon membrane filter (BD Biosciences). Splenocytes were then subjected to Ficoll-
Paque PREMIUM density gradient centrifugation to obtain mononuclear cells. DC-
SIGN expression on the splenocytes was investigated by flow cytometry using
fluorochrome-conjugated monoclonal antibodies and data were analyzed by
FACSDivaTM and FlowJo softwares.
Stimulation of cells.Mo-DCs (0.5 3 106/ml) were cultured in RPMI 1640-10% FCS
containing GM-CSF and IL-4 in a 12-well plate. The cells were then exposed to IVIg
(25 mg/ml) for 48 hours to analyze the effect of IVIg on IL-33 production under non-
inflammatory conditions. In parallel, Mo-DCs were stimulated with either TLR4
ligand lipopolysaccharide (100 ng/ml/0.5 3 106 cells) (Sigma-Aldrich, France) or
inflammatory cytokine cocktail (10 ng/ml each of IL-1b, IL-6 and TNF-a, all from
ImmunoTools, Germany)57. After four hours, IVIg was added and cultures were
maintained for 48 hours to analyze the effect of IVIg on IL-33 production under
inflammatory conditions.
Similarly, splenocytes (0.5 3 106/ml) were cultured in RPMI 1640-10% FCS for
48 hours either alone or with IVIg. In addition, splenocytes were also stimulated with
inflammatory cytokine cocktail and IVIg was added to the cultures after four hours.
The cultures were maintained for 48 hours.
Quantification of cytokines. IL-33 in the plasma samples of the patients and in cell-
free culture supernatants was quantified by ELISA (R&D systems, France). IL-4 in the
plasma was also measured by ELISA (R&D systems).
Statistical analysis. Data was analyzed using Prism 5 software (GraphPad software).
Two-tailed Student’s t-test was used to determine the statistical significance of the
data. Values of P , 0.05 were considered as statistically significant.
1. Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular
diseases. JAMA 291, 2367–2375 (2004).
2. Kazatchkine, M. D. & Kaveri, S. V. Immunomodulation of autoimmune and
inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345,
747–755 (2001).
3. Arnson, Y., Shoenfeld, Y. & Amital, H. Intravenous immunoglobulin therapy for
autoimmune diseases. Autoimmunity 42, 553–560 (2009).
4. Bayry, J., Negi, V. S. & Kaveri, S. V. Intravenous immunoglobulin therapy in
rheumatic diseases. Nat. Rev. Rheumatol. 7, 349–359 (2011).
5. Schwab, I. &Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG
modulate the immune system? Nat. Rev. Immunol. 13, 176–189 (2013).
6. Seite, J. F., Shoenfeld, Y., Youinou, P. & Hillion, S. What is the contents of the
magic draft IVIg? Autoimmun. Rev. 7, 435–439 (2008).
7. Tha-In, T., Bayry, J., Metselaar, H. J., Kaveri, S. V. & Kwekkeboom, J. Modulation
of the cellular immune system by intravenous immunoglobulin. Trends Immunol.
29, 608–615 (2008).
8. Ballow, M. The IgG molecule as a biological immune response modifier:
Mechanisms of action of intravenous immune serum globulin in autoimmune
and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315–323 (2011).
9. Jordan, S. C., Toyoda, M. & Vo, A. A. Intravenous immunoglobulin a natural
regulator of immunity and inflammation. Transplantation 88, 1–6 (2009).
10. Semple, J. W. et al. Intravenous immunoglobulin prevents murine antibody-
mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS)
production. PLoS One 7, e31357 (2012).
11. Bayry, J. et al. Intravenous immunoglobulin abrogates dendritic cell
differentiation induced by interferon-alpha present in serum from patients with
systemic lupus erythematosus. Arthritis Rheum. 48, 3497–3502 (2003).
12. Aubin, E., Lemieux, R. & Bazin, R. Indirect inhibition of in vivo and in vitro T-cell
responses by intravenous immunoglobulins due to impaired antigen presentation.
Blood 115, 1727–1734 (2010).
13. Maddur, M. S. et al. Inhibition of differentiation, amplification, and function of
human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol.
127, 823–830 e821–827 (2011).
14.Maddur, M. S., Kaveri, S. V. & Bayry, J. Comparison of different IVIg preparations
on IL-17 production by human Th17 cells. Autoimmun. Rev. 10, 809–810 (2011).
15. Maddur, M. S. et al. Inhibitory effect of IVIG on IL-17 production by Th17 cells is
independent of anti-IL-17 antibodies in the immunoglobulin preparations. J. Clin.
Immunol. 33, S62–S66 (2013).
16. Kessel, A. et al. Intravenous immunoglobulin therapy affects T regulatory cells by
increasing their suppressive function. J. Immunol. 179, 5571–5575 (2007).
17. De Groot, A. S. et al. Activation of natural regulatory T cells by IgG Fc- derived
peptide ‘‘Tregitopes’’. Blood 112, 3303–3311 (2008).
18. Massoud, A. H. et al. Intravenous immunoglobulin attenuates airway
inflammation through induction of forkhead box protein 3-positive regulatory T
cells. J. Allergy Clin. Immunol. 129, 1656–1665 e1653 (2012).
19. Trinath, J. et al. Intravenous immunoglobulin expands regulatory T cells via
induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic
cells. Blood 122, 1419–1427 (2013).
20. Seite, J. F., Goutsmedt, C., Youinou, P., Pers, J. O. & Hillion, S. Intravenous
immunoglobulin induces a functional silencing program similar to anergy in
human B cells. J. Allergy Clin. Immunol. 133, 181–188 e181–189 (2014).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5672 | DOI: f10.1038/srep05672 5
21. Massoud, A. H. et al. Dendritic cell immunoreceptor: a novel receptor for
intravenous immunoglobulin mediates induction of regulatory T cells. J. Allergy
Clin. Immunol. 133, 853–863 e855 (2014).
22. Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous
gammaglobulin suppresses inflammation through a novel T(H)2 pathway.
Nature 475, 110–113 (2011).
23. Voehringer, D. Protective and pathological roles of mast cells and basophils. Nat.
Rev. Immunol. 13, 362–375 (2013).
24. Otsuka, A. et al. Basophils are required for the induction of Th2 immunity to
haptens and peptide antigens. Nat. Commun. 4, 1739, doi:10.1038/ncomms2740
(2013).
25. Sharma, M. et al. Circulating human basophils lack the features of professional
antigen presenting cells. Sci. Rep. 3, 1188, doi: 10.1038/srep01188 (2013).
26. Campbell, I. K. et al. Therapeutic effect of IVIG on inflammatory arthritis in mice
is dependent on the Fc portion and independent of sialylation or basophils.
J. Immunol. 192, 5031–5038 (2014).
27. von Gunten, S. et al. IVIG pluripotency and the concept of Fc-sialylation:
challenges to the scientist. Nat. Rev. Immunol. 14, 349 (2014).
28. Abe, J. et al. Gene expression profiling of the effect of high-dose intravenous Ig in
patients with Kawasaki disease. J. Immunol. 174, 5837–5845 (2005).
29. Shimomura, M. et al. Intravenous immunoglobulin does not increase FccRIIB
expression levels on monocytes in children with immune thrombocytopenia.
Clin. Exp. Immunol. 169, 33–37 (2012).
30. Barnett, C. et al. Fcc receptor polymorphisms do not predict response to
intravenous immunoglobulin in myasthenia gravis. J. Clin. Neuromuscul. Dis. 14,
1–6 (2012).
31. Yu, H. R. et al. DC-SIGN (CD209) promoter -336 A/G (rs4804803)
polymorphism associated with susceptibility of Kawasaki disease. Sci. World J.
2012, 634835 (2012).
32. Ogata, S. et al. Treatment response in kawasaki disease is associated with
sialylation levels of endogenous but not therapeutic intravenous immunoglobulin
G. PLoS One 8, e81448 (2013).
33. Bayry, J., Bansal, K., Kazatchkine, M. D. & Kaveri, S. V. DC-SIGN and a2,6-
sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of
IVIg on human dendritic cells. Proc. Natl. Acad. Sci. U S A. 106, E24 (2009).
34. Wiedeman, A. E. et al. Contrasting mechanisms of interferon-alpha inhibition by
intravenous immunoglobulin after induction by immune complexes versus Toll-
like receptor agonists. Arthritis Rheum. 65, 2713–2723 (2013).
35. Anthony, R.M.,Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a
receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci.
U S A. 105, 19571–19578 (2008).
36. Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a
recombinant IgG Fc. Science 320, 373–376 (2008).
37. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of
immunoglobulin G resulting from Fc sialylation. Science 313, 670–673 (2006).
38. Guhr, T. et al. Enrichment of sialylated IgG by lectin fractionation does not
enhance the efficacy of immunoglobulin G in a murine model of immune
thrombocytopenia. PLoS One 6, e21246 (2011).
39. Ramakrishna, C., Newo, A. N., Shen, Y. W. & Cantin, E. Passively administered
pooled human immunoglobulins exert IL-10 dependent anti- inflammatory
effects that protect against fatal HSV encephalitis. PLoS Pathog. 7, e1002071
(2011).
40. Kasermann, F. et al. Analysis and functional consequences of increased Fab-
sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS
One 7, e37243 (2012).
41. Leontyev, D. et al. Sialylation-independent mechanism involved in the
amelioration of murine immune thrombocytopenia using intravenous
gammaglobulin. Transfusion 52, 1799–1805 (2012).
42. Leontyev, D., Katsman, Y. & Branch, D. R. Mouse background and IVIG dosage
are critical in establishing the role of inhibitory Fcgamma receptor for the
amelioration of experimental ITP. Blood 119, 5261–5264 (2012).
43. Othy, S. et al. Intravenous gammaglobulin inhibits encephalitogenic potential of
pathogenic T cells and interferes with their trafficking to the central nervous
system, implicating sphingosine-1 phosphate receptor 1-mammalian target of
rapamycin axis. J. Immunol. 190, 4535–4541 (2013).
44. Othy, S. et al. Sialylationmay be dispensable for reciprocal modulation of helper T
cells by intravenous immunoglobulin. Eur. J. Immunol. (epub ahead of print)
doi:10.1002/eji.201444440 (2014).
45. Crispin, M., Yu, X. & Bowden, T. A. Crystal structure of sialylated IgG Fc:
implications for the mechanism of intravenous immunoglobulin therapy. Proc.
Natl. Acad. Sci. U S A. 110, E3544–3546 (2013).
46. Yu, X., Vasiljevic, S., Mitchell, D. A., Crispin, M. & Scanlan, C. N. Dissecting the
molecular mechanism of IVIg therapy: the interaction between serum IgG and
DC-SIGN is independent of antibody glycoform or Fc domain. J. Mol. Biol. 425,
1253–1258 (2013).
47. Grotenboer, N. S., Ketelaar, M. E., Koppelman, G. H. & Nawijn, M. C. Decoding
asthma: translating genetic variation in IL33 and IL1RL1 into disease
pathophysiology. J. Allergy Clin. Immunol. 131, 856–865 (2013).
48. Williams, J. W. et al. Transcription factor IRF4 drives dendritic cells to promote
Th2 differentiation. Nat. Commun. 4, 2990, doi:10.1038/ncomms3990 (2013).
49. Schwab, I., Biburger, M., Kronke, G., Schett, G. &Nimmerjahn, F. IVIg- mediated
amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J.
Immunol. 42, 826–830 (2012).
50. Bonilla, W. V. et al. The alarmin interleukin-33 drives protective antiviral CD81
T cell responses. Science 335, 984–989 (2012).
51. Cayrol, C. & Girard, J. P. The IL-1-like cytokine IL-33 is inactivated after
maturation by caspase-1. Proc. Natl. Acad. Sci. U S A. 106, 9021–9026 (2009).
52. Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J. & Kuchler, A. M.
Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol. 30,
227–233 (2009).
53. Prasad, N. K. et al. Therapeutic preparations of normal polyspecific IgG (IVIg)
induce apoptosis in human lymphocytes and monocytes: a novel mechanism of
action of IVIg involving the Fas apoptotic pathway. J. Immunol. 161, 3781–3790
(1998).
54. von Gunten, S. et al. Immunologic and functional evidence for anti-Siglec-9
autoantibodies in intravenous immunoglobulin preparations. Blood 108,
4255–4259 (2006).
55. Moussion, C., Ortega, N. & Girard, J. P. The IL-1-like cytokine IL-33 is
constitutively expressed in the nucleus of endothelial cells and epithelial cells in
vivo: a novel ‘alarmin’? PLoS One 3, e3331 (2008).
56. Maddur, M. S. et al. Human B cells induce dendritic cell maturation and favour
Th2 polarization by inducing OX-40 ligand. Nat. Commun. 5, 4092, doi:10.1038/
ncomms5092 (2014).
57. Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18,
767–811 (2000).
Acknowledgments
This study was supported by Institut National de la Sante´ et de la Recherche Me´dicale
(INSERM), Centre National de la Recherche Scientifique (CNRS), Universite´ Pierre et
Marie Curie, Universite´ Paris Descartes and European Community’s Seventh Framework
Programme [FP7/2007–2013] under grant agreement HEALTH-2010.2.4.5-2 ALLFUN.
We also thank Laboratoire Français du Fractionnement et des Biotechnologies, France for
the support.
Author contributions
J.B. designed the research, M.S., C.S., P.H., M.S.M., E.S-V., L.G. & M.L. performed the
experiments, M.S., P.H., M.S.M., S.V.K. & J.B. analyzed the data, Y.S., L.M. &O.B. provided
blood samples of the patients, P.B. provided the spleen tissues, J.B. wrote the paper and all
authors reviewed and approved the manuscript.
Additional information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Sharma, M. et al. Intravenous immunoglobulin-induced IL-33 is
insufficient to mediate basophil expansion in autoimmune patients. Sci. Rep. 4, 5672;
DOI:f10.1038/srep05672 (2014).
This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 4.0 International License. The images or other third party material in
this article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder
in order to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5672 | DOI: f10.1038/srep05672 6
